YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- PHAT shareholders absorbed the loss when Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) issued FY 2026 revenue guidance with a high end of $325 million -- below Wall Street expectations of approxim…
Earnings Call Insights: Phathom Pharmaceuticals (PHAT) Q2 2026 MANAGEMENT VIEW * "For the first time in Phathom's history and ahead of our guidance, we generated positive operating profit in Q2, excluding stock-based compensation." (CEO, P…
(RTTNews) - Phathom Pharmaceuticals, Inc. (PHAT), which develops treatments for gastrointestinal diseases, on Tuesday announced that it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA (vonoprazan)…
Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Moby Strategic Execution and Market Dynamics Revenue more than doubled year-over-year, driven by the strategic pivot to prioritize high-frequency engagement with gastroenterolog…
Image source: The Motley Fool. Date Thursday, Apr. 30, 2026 at 8 a.m. ET Call participants President and Chief Executive Officer — Steven Basta Chief Financial and Business Officer — Sanjeev Narula Vice President, Investor Relations — Eric…
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $1.07 per share a year ago. These figures are adjusted for non-recurr…
DelveInsight Business Research LLP The eosinophilic esophagitis market is witnessing steady growth, primarily driven by the increasing awareness leading to standardized diagnosis and high relapse rates that continue to fuel ongoing treatme…
[Sign for Wall Street in New York City] Pharrel Wiliams * Barclays upgraded Phathom Pharmaceuticals (PHAT [https://seekingalpha.com/symbol/PHAT]) to overweight from equal weight following a huge share decline year to date on growing indica…
Quick Read Phathom Pharmaceuticals (PHAT) saw quarterly prescription fills jump from 127,000 in Q1 2025 to 273,000 in Q4 2025, driving Q4 revenue to $57.58M (up 94% year-over-year) with EPS of -$0.08 beating consensus by -$0.34, while Barc…
Shares of Ocugen OCGN declined 8.6% on Tuesday after the company announced 12-month data from the phase II ArMaDa study evaluating its novel modifier gene therapy, OCU410, for treating geographic atrophy (GA) secondary to dry age-related m…
Shares of ImmunityBio IBRX were up 11% on Monday after the company announced that Macau’s regulatory body has approved its lead drug, Anktiva, for treating certain patients with a type of bladder cancer. The regulatory body has approved An…
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in United Rentals Inc (Symbol: URI), where a total volume of 5,847 contracts has been traded thus far today, a contract volu…
Shares of Puma Biotechnology PBYI have tanked 9.6% in the past month, reflecting the growing investor concern regarding the company’s soft 2026 revenue outlook. The company’s sole marketed product, Nerlynx (neratinib), is approved for trea…
Mirum Pharmaceuticals MIRM announced that it has completed enrollment in the phase III EXPAND study, which evaluated Livmarli (maralixibat) for treating cholestatic pruritus in patients aged six months and above with rare cholestatic liver…
Cogent Biosciences COGT announced that the FDA has accepted the new drug application (“NDA”) seeking approval for its lead pipeline candidate, bezuclastinib, for treating patients with non-advanced systemic mastocytosis (NonAdvSM). With th…
Shares of Mineralys Therapeutics MLYS were up 4.4% yesterday after the company announced that the FDA has accepted the new drug application (NDA) for its product candidate, lorundrostat, to treat adult patients with hypertension in combina…
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Intuit Inc (Symbol: INTU), where a total of 32,692 contracts have traded so far, representing approximately 3.3 million underlying…
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) is one of the best cheap biotech stocks to buy now. Guggenheim lifted the price target on Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) to $25 from $20 on February 27, maintaining a Buy rating on t…
Major earnings expected before the bell on Thursday include: * Viatris (VTRS [https://seekingalpha.com/symbol/VTRS]) * Baidu (BIDU [https://seekingalpha.com/symbol/BIDU]) * Vistance Networks (VISN [https://seekingalpha.com/symbol/VISN]) *…
Phathom Pharmaceuticals logo Key Points Phathom is building its business around VOQUEZNA (vonoprazan), reporting $55 million in 2024 revenue and an estimated $175 million for 2025, and expects to reach operating profitability in the second…
* Phathom Pharmaceutical (PHAT [https://seekingalpha.com/symbol/PHAT]) priced [https://seekingalpha.com/pr/20357206-phathom-pharmaceuticals-announces-pricing-of-130-million-public-offering-of-common-stock-and] an underwritten public offeri…
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today…
* Phathom Pharmaceuticals (PHAT [https://seekingalpha.com/symbol/PHAT]) said on Wednesday it plans a public offering of common stock and pre-funded warrants, subject to market conditions, shortly after reporting preliminary [https://seekin…
CHICAGO and NEW YORK, Jan. 6, 2026 /PRNewswire/ -- Opal Holdings LLC ("Opal"), a national commercial real estate owner and operator founded by Shaya Prager, announced today that it has successfully executed approximately 250,000 square fee…
(RTTNews) - Biotech names dominated the after-hours session on Friday, with several companies posting notable gains despite limited news catalysts. GH Research PLC (GHRS) surged the most, climbing 22.36% to $16.20, up $2.96. The sharp move…
As December draws to a close and Christmas arrives, investors are pausing to look back and assess a year that never followed a simple script. Policy uncertainty lingered, and trade headlines remained unpredictable as President Trump contin…
The S&P 500 Index ($SPX) (SPY) today is down by -0.86%, the Dow Jones Industrials Index ($DOWI) (DIA) is down by -0.39%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down by -1.85%. December E-mini S&P futures (ESZ25) are down -0.85%, and Dec…
The S&P 500 Index ($SPX) (SPY) today is down by -0.20%, the Dow Jones Industrials Index ($DOWI) (DIA) is up by +0.16%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down by -0.75%. December E-mini S&P futures (ESZ25) are down -0.22%, and Decem…
The S&P 500 Index ($SPX) (SPY) today is down by -0.86%, the Dow Jones Industrials Index ($DOWI) (DIA) is down by -0.39%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down by -1.85%. December E-mini S&P futures (ESZ25) are down -0.85%, and Dec…
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied…
Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including clinically meaningful increases in heart…
FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced…
Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and comm…
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied…
FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August 20, will include adm…
Earnings Call Insights: Phathom Pharmaceuticals (PHAT) Q2 2025 MANAGEMENT VIEW * Steven L. Basta, CEO, indicated that the quarter marked "a meaningful inflection point for Phathom" as the company builds a growth-oriented and profitable GI…